Genetic testing for families at risk of pancreatic cancer in Italy
Official title: Standardised Genetic Profiling of Subjects Belonging to the Italian Multicenter Registry of Prospective Surveillance of Subjects at Genetic Risk of Pancreatic Cancer
Run by Associazione Italiana per lo Studio del Pancreas · NCT05724992 · Data updated 2026-11-12
This study is testing a genetic test for family members of pancreatic cancer patients in Italy to see if it can help identify those at risk and improve their chances of prevention.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 3000 (estimated) |
| Sponsor | Associazione Italiana per lo Studio del Pancreas Academic / other |
| Locations | 1 site (Verona) |
| Status | Recruiting |
| Started | December 20, 2022 |
| Main results expected | December 20, 2027 |
| Study ends | December 20, 2028 |
| Registry record updated | February 15, 2023 |
| Trial ID | NCT05724992 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are family members of pancreatic cancer patients who are enrolled in the Italian Registry of Families At Risk of Pancreatic Cancer and have a familial history of the disease.
✕Probably not a fit
Patients who already have a known genetic mutation related to pancreatic cancer will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The PROPH-ITA program aims to conduct genetic testing on family members of pancreatic cancer patients who may have a hereditary predisposition to the disease. Participants will be recruited from the Italian Registry of Families At Risk of Pancreatic Cancer and will undergo a saliva-swab-based genetic test that analyzes 41 specific genes. The study seeks to enroll up to 3,000 individuals to better understand the genetic factors associated with familial pancreatic cancer. This approach could enhance surveillance and preventive strategies for those at risk.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection and prevention strategies for individuals genetically predisposed to pancreatic cancer.
How similar studies have gone: Other studies focusing on genetic testing for hereditary pancreatic cancer have shown promise, indicating that this approach is both relevant and potentially impactful.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Being enrolled on the IRFARPC registry * Having familiarity for pancreatic cancer (according to the IRFARPC criteria, Capurso et al. Dig Liv Dis, 2020) * Willingness to participate in saliva-swab-based genetic testing Exclusion Criteria: \- Already known genetic mutation
Where it's running
-
Chirurgia generale e del Pancreas Azienda Ospedaliera Universitaria Integrata
Verona, Italy Recruiting
Study contacts
- Study coordinator: Erica Secchettin, PharmD
- Email: familiarita.aisp@gmail.com
- Phone: 0458126254
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.